Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based On Home Systolic Pressure (HOSP) substudy

Clinical and Experimental Hypertension

Volumn 32, Issue 4, 2010, Pages 239-243

  Kawano, Yuhei ^a   Horio, Takeshi ^a   Kamide, Kei ^a   Iwashima, Yoshio ^a   Yoshihara, Fumiki ^a   Nakamura, Satoko ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Amlodipine; Antihypertensive therapy; Home blood pressure (BP); Hypertension; Losartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; LOSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; FEASIBILITY STUDY; JAPAN; MIDDLE AGED; PILOT STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTENSION; JAPAN; LOSARTAN; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954473111     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.491889     Document Type: Article

References (27)

1. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power than dose screening blood pressure measurement: A population-based observation in Ohasama, Japan. J Hypertens 1998;16:971-975.
2. Tsunoda S, Kawano Y, Horio T, Okuda N, Takishita S. Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients. Hypertens Res 2002;25:167-173.
3. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-1349.
4. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioi Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777-1783.
5. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993;153:598-615.
6. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality. Arch Intern Med 2001;161:1183-1192.
7. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-743.
8. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401-1406.
9. Kawano Y, Mannami T, Saitoh D, et al. Hypertension Control based on home systolic pressure (HOSP): Study design and interim report. J Hypertens 2002;20 (suppl 4):S162.
10. Kawano Y, Mannami T, Saitoh D, et al. Hypertension control based on home systolic pressure (HOSP) study: Design and interim report of the main study. J Hypertens 2006;20 (suppl 6):329.
11. Kawano Y, Nakamura S, Horio T, et al. Control of home blood pressure and urinary albumin excretion in patients with essential hypertension: HOSP substudy. Ther Res 2002;23: 790-793 (in Japanese).
12. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-1187.
13. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
14. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and United States. Arch Intern Med 2007;167:141-147.
15. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827.
16. Prospective studies collaboration: Age specific relevance of usual blood pressure to vascular mortality: A meta-analysis if individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
17. Blood pressure lowering treatment trialists' collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2004;352:1527-1535.
18. Ohkubo T, Obara T, Funahashi J, et al. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Rvaluation (J-HOME) study. Hypertens Res 2004;27:755-763.
19. Kawano Y. Horio T, Matayoshi T, Kamide K. Masked hypertension: subtypes and target organ damage. Clin Exp Hypertens 2008;30:289-296.
20. Staessen JA, Den Hond E, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physicians' office. JAMA 2004;291:955-964.
21. Cappuccio FP, Kerry SM, Forbes M, Donald A. Blood pressure control by home monitoring: mata-analysis of randomized trials. Br Med J 2004;329:145-148.
22. Fujiwara T, Nishimura T, Ohkubo T, Imai Y. Rationale and design of HOMED-BP study: Hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 2002;7:77-82.
23. Ohtawa H, Takayama F, Saitoh K, et al. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active angiotensin II receptor antagonist in humans. Br J Clin Pharmacol 1993;35:290-297.
24. Motomura S, Hashimoto K. Classification and pharmacokinetics of calcium antagonists. All about calcium antagonist. Saryta T, Hiwada K, Ogihara T, eds. Tokyo: Sentan Igaku Co., pp. 30-54, 1999.
25. Nishimura T, Hashimoto J, Ohkubo T, et al. Efficacy and duration of action of the four selective angiotensin II receptor blockers, losartan, candesartan, valsartan, and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005;27:477-489.
26. Minami J, Ishimitsu T, Kawano Y, Matsuoka H. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998;25: 572-576.
27. Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for the Grobal Renal Protection in Hypertensive Patients (JLIGHT). Hypertens Res 2004;27:21-30.